세계의 항파킨슨병제 시장 규모는 2025년 61억 달러에서 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 8.6%로 추이하고 2030년 말에는 92억 달러에 달할 것으로 예측되고 있습니다.
북미 시장은 2025년 35억 달러에서 예측 기간 동안 9.5%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년 말에는 55억 달러에 이를 것으로 예측되고 있습니다. 유럽 시장은 2025년 14억 달러에서 예측 기간 동안 CAGR 8%로 추이하고 2030년 말에는 20억 달러에 달할 것으로 예측되고 있습니다.
본 보고서에서는 세계의 항파킨슨병제 시장을 조사했으며, 시장 개요, 시장 영향인자 및 시장 기회 분석, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석 등을 정리했습니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
개요
현재의 시장 시나리오
부문 분석
신흥기술
결론
제2장 시장 개요
개요 및 시장 정의
병태생리학
증상
진단
치료 및 관리
거시경제 요인분석
인구통계학적 요인
환경 요인
지정학적 요인
경제적 요인
미국의 관세가 항파킨슨병제 시장에 미치는 영향
Porter's Five Forces 분석
공급망 분석
제3장 시장 역학
시장 역학
시장 성장 촉진요인
파킨슨병의 유병률
높은 미충족 요구가 혁신으로 이어질 것
업계 제휴에 의한 연구 개발 가속
공적 및 민간 투자 및 지원 증가
시장 성장 억제요인
항파킨슨병제에 수반하는 부작용
의약품 개발의 높은 비용과 낮은 성공률
시장 기회
신흥국에서의 의식 고조
견고한 파이프라인
제4장 규제 상황
항파킨슨병제의 규제
미국
유럽
일본
제5장 신기술과 개발
신흥기술
약제와 의료기기 조합
세포 및 유전자 치료
백신
단일클론항체
기타 병용 요법
파이프라인 분석
중요 포인트
제6장 시장 세분화 분석
개요
중요 포인트
세분화의 내역
시장 분석 : 약제 클래스별
도파민 작용제
도파민 작용제
카테콜-O-메틸트랜스퍼라제 억제제
모노아민 산화 효소 B 억제제
항콜린제
기타
지리적 내역
시장 분석 : 지역별
중요 포인트
북미
유럽
아시아태평양
기타 지역
제7장 경쟁 정보
중요 포인트
시장 점유율 분석
전략적 노력
협정, 협력, 파트너십
인수
제8장 세계 항파킨슨병제 시장의 지속가능성 : ESG의 관점
ESG: 소개
지속가능성의 동향과 대처
환경
사회와 거버넌스의 대처
ESG 위험 평가
결론
제9장 부록
조사 방법
출처
약어
기업 프로파일
ABBVIE INC.
CADIA PHARMACEUTICALS INC.
AMNEAL PHARMACEUTICALS LLC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
KYOWA KIRIN CO. LTD.
MERZ THERAPEUTICS
NEUROCRINE BIOSCIENCES INC.
NEURODERM
NEWRON PHARMACEUTICALS SPA
NOVARTIS AG
PFIZER INC.
SUPERNUS PHARMACEUTICALS INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
신흥 스타트업 기업/시장 디스럽터
JHS
영문 목차
영문목차
The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.
The North American market for anti-Parkinson’s drugs is projected to grow from $3.5 billion in 2025 to reach $5.5 billion by the end of 2030, at a CAGR of 9.5% from 2025 to 2030.
The European market for anti-Parkinson’s drugs is projected to grow from $1.4 billion in 2025 to reach $2.0 billion by the end of 2030, at a CAGR of 8% from 2025 to 2030.
Report Scope
The report provides an overview of the global anti-Parkinson's drugs market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimated data for 2025 and forecast of compound annual growth rates (CAGRs) from 2025 to 2030. The market is segmented by drug class (based on mechanisms of action) and regions. By drug class, the market is segmented into dopaminergic, dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase-B (MAO-B) inhibitors, anticholinergic and others. The regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific. The report focuses on the driving trends and challenges affecting the market. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report also includes an analysis of the competitive landscape and company profiles that address such details as overview, key financials, product portfolio and recent developments of key market businesses.
Report Includes
46 data tables and 55 additional tables
An overview of the global market for anti-Parkinson's drugs
In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, forecasts for 2030 and projections of compound annual growth rates (CAGRs) through 2030
Evaluation of the current market size and revenue growth prospects specific to anti-Parkinson's drugs, accompanied by a market share analysis by drug class and region
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends in the market
Insights derived from Porter's Five Forces model, global value chain and case studies
Patent analysis and emerging trends and developments in patent activity
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Identification of companies best positioned to meet this demand due to their proprietary technologies, M&As, joint ventures and other strategic alliances
Descriptive profiles of leading companies, including AbbVie Inc., Amneal Pharmaceuticals LLC., Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., and Teva Pharmaceutical Industries Co. Ltd.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Pathophysiology
Symptoms
Diagnosis
Treatment and Management
Macroeconomic Factors Analysis
Demographic Factors
Environmental Factors
Geopolitical Factors
Economic Factors
Impact of U.S. Tariffs on the Anti-Parkinson's Drugs Market
Porter's Five Forces Analysis
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitute Products or Services (Moderate to High)
Industry Rivalry (High)
Supply Chain Analysis
Research and Development (R&D)
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Prevalence of Parkinson's Disease
High Unmet Treatment Need Leads to Innovation
Industry Collaborations Accelerate R&D
Increased Public and Private Investments and Support
Market Restraints
Adverse Effects Associated with Anti-Parkinson's Drugs
High Cost of Drug Development and Low Success Rate
Market Opportunities
Increased Awareness in Emerging Countries
Robust Pipeline
Chapter 4 Regulatory Landscape
Regulatory Aspects of Anti-Parkinson's Drugs
United States
Europe
Japan
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Drug-Device Combinations
Cell and Gene Therapies
Vaccine
Monoclonal Antibodies
Other Combination Therapies
Pipeline Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Overview
Key Takeaways
Segmentation Breakdown
Market Analysis by Drug Class
Dopaminergic
Dopamine Agonists
Catechol-O-methyl Transferase Inhibitors
Monoamine Oxidase B Inhibitors
Anticholinergics
Others
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Market Share Analysis
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Chapter 8 Sustainability in the Anti-Parkinson's Drugs Global Market: An ESG Perspective
